VCJ Staff

VMWare Buying SpringSource for $420 Million

Domain Associates Raises 8th Fund

Domain Associates, a healthcare-focused VC firm, has closed its eighth fund with $500 million in capital commitments. It reportedly had targeted $700 million, which is the same amount it raised for its seventh fund back in 2006.

Cmosis Raises €3 Million

CMOSIS NV, an Antwerp, Belgium-based maker of CMOS image sensors, has raised €3 million in new VC funding. ING Corporate Investments led the round, and was joined by ING Activator Fund and Vlaams Innovatiefonds.

Facebook Acquires FriendFeed

Facebook has acquired FriendFeed Inc., a Mountain View, Calif.-based social networking site focused on content sharing. No financial terms have been disclosed. Friendfeed raised a $5 million in Series A funding in Ferbruary 2008. Benchmark Capital led the round, and was joined by company co-founders Paul Buchheit and Sanjeev Singh. Facebook investors include Accel Partners, Greylock Partners, Meritech Capital Partners, Microsoft and Millennium Technology Ventures.

Enobia Pharma Raises $50 Million

Enobia Pharma Inc., a Montreal-based developer of enzyme replacement therapies for the treatment of serious bone diseases, has raised US$50 million in Series C funding. Return backers include OrbiMed Advisors, CTI Life Sciences Fund, Fonds de solidarite FTQ, Desjardins Venture Capital and Lothian Partners. Enobia's lead candidate focuses on hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone.

Fortinet Files for $100 Million IPO

Amalfi Semiconductor Raises $24 Million

Amalfi Semiconductor, a Los Gatos, Calif.-based developer of CMOS RF and mixed-signal chips, has raised $24 million in Series C funding. Battery Ventures led the round, and was joined by return backers DCM, Globespan Capital Partners and Trinity Ventures. The company previously raised around $33 million.

Ex-VCs Form Biopharma Consultancy

Report: Opus Capital Raising New Fund

Autism Drugmaker Raises $6.5 Million

Curemark, a Rye, N.Y.-based developer of drugs that address certain gastrointestinal and pancreatic secretory deficiencies, has raised $6.5 million in Series A funding. No investor information was disclosed. The company's lead candidate focuses on autism, and will soon enter Phase III clinical trials.